Summary
Applied StemCell, Inc. is a leading stem cell and gene-editing company
focusing on the development of products and therapeutics that are enabled by
its proprietary gene editing platform technologies. This bay area bio-tech
company published a press release on June 6 through business wire to disclose a
Series D investment round of $19 million. The Series D financing is led by
HerMed Capital. Additional investors included Ping An Ventures, Vi-Ventures and
BioScikin. The company intends to use the proceeds to accelerate the
development of its pipeline, expand its gene editing platform technology, as
well as to continue to strengthen its leading intellectual property portfolio.
No comments:
Post a Comment